New Aspects in Diabetes

Name: New Aspects in Diabetes | Treatment Strategies with Alpha-Glucosidase Inhibitors. Third International Symposium on Acarbose
Brand: De Gruyter
Price: 109.95 EUR
Availability: OnlineOnly

Treatment Strategies with Alpha-Glucosidase Inhibitors. Third International Symposium on Acarbose

Pierre J. Lefèbvre Eberhard Standl(Herausgeber*in)

De Gruyter (Verlag)

1. Auflage

Erschienen am 22. Juli 2019

XII, 294 Seiten

E-Book

PDF mit Wasserzeichen-DRM

Systemvoraussetzungen

978-3-11-085944-7 (ISBN)

109,95 €inkl. 7% MwSt.

Systemvoraussetzungen

für PDF mit Wasserzeichen-DRM

E-Book Einzellizenz

Als Download verfügbar

Beschreibung

Weitere Details

Weitere Ausgaben

Inhalt

Intro
List of first-mentioned contributors
Contents
Introduction
I. New aspects in diabetes mellitus
The epidemiology of diabetes mellitus and its relationship with cardiovascular disease
Syndrome X: fact or fiction?
Strategies for the treatment of hyperglycemia in Syndrome X
Treatment strategies of Syndrome X - hypertension and vascular complications
Lipid metabolism: metabolic consequences of moderate hypertriglyceridemia
Update on the treatment of NIDDM
Hyperinsulinemia and macrovascular complications in NIDDM
II. Quality of life in diabetes mellitus
Diabetes and quality of life: some current issues in definition and research
Quality of life in patients with type II diabetes mellitus
Well-being in non-insulin-dependent diabetic patients (NIDDM) - a long-term follow-up
III. Studies with acarbose
Acarbose monotherapy in non-insulin-dependent diabetes mellitus - the German experience
Acarbose in non-insulin-dependent diabetes mellitus: combination with sulfonylureas and interaction with diet
Clinical efficacy of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus (NIDDM) - a placebo-controlled double-blind comparative study
Effects of long-term administration of acarbose in patients with NIDDM - a double-blind study with placebo
Effects of acarbose on blood glucose control in insulindependent diabetes mellitus
European experience in the treatment of IDDM with acarbose in combination with insulin
Round table discussion on open questions and future aspects
IV. Abstracts
A multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (BAYg 5421) in the treatment of obese patients with NIDDM treated by diet alone
A multi-center, double-blind, placebo-controlled study of long-term efficacy and safety of acarbose (BAY g 5421) and sulfonylureas in the treatment of NIDDM inadequately controlled by maximal doses of sulfonylureas (SFU)
A multi-center, double-blind, comparative study of the long-term efficacy and safety of acarbose (BAY g 5421) vs. placebo in the treatment of patients with insulin requiring type II diabetes mellitus
Prospective, multi-center studies of the efficacy and safety of acarbose (BAY g 5421) in the treatment of type I diabetes mellitus
Two multi-center, double-blind, placebo-controlled studies of efficacy and safety of acarbose treatment of type I diabetes
Clinical study of reduced postprandial hyperglycemia by acarbose and glycemic impact of fructose and sucrose in insulin therapy
6 months monotherapy of NIDDM with acarbose or glibenclamide
Decreased insulin requirement and postprandial insulin plasma concentrations under treatment with the a-glucosidase inhibitor acarbose
Long-term treatment of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus
Clinical efficacy and tolerability of acarbose in IDDM treatment
Effects of acarbose on the glycemic index of different foods
Effects of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in type II diabetics
Influence of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in healthy volunteers
Acarbose: an intestinal tract a-glucosidase inhibitor - pharmacological effects on insulin and glycemia in response to a sucrose load
Assessment of efficacy and tolerability of acarbose (Glucobay⊃&®&/sup&) by clinical data pool
Long-term tolerability of acarbose
Assessment of efficacy and tolerability of acarbose in diabetic patients 5 - 16 years of age
Effect of acarbose repeated dosing on antipyrine test in healthy volunteers
Discussion

Systemvoraussetzungen

Als PDF speichern Als Link merken